PET scan imaging to predict prostate cancer treatment response
Studies PSMA PET scans to predict response in adults with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
Key facts
- Where
- Bologna, Cuneo, Genova, and Messina, ItalySee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with advanced prostate cancer who are about to start a drug treatment and are having a PSMA PET scan to stage the disease first.
- Age
- 18 years or older.
- Sex
- Men only.
- Disease stage
- Advanced prostate cancer confirmed by tissue examination; neuroendocrine carcinoma is not included.
- Earlier treatment
- Must be about to receive one or more of: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA.
Main reasons for not taking part
- Cannot lie still on the back for the PET/CT scan
- Prostate cancer with a known significant neuroendocrine component
- Another cancer at the same time, except non-melanoma skin cancer
Read by machine on 12 November 2026.
Where in Italy
- Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyContact: Andrea Farolfi, MDTaking people
- Azienda Ospedaliera Santa Croce e Carle - ospedale Santa CroceCuneo, ItalyContact: Virgini Liberini, MDTaking people
- U.O. Medicina Nucleare, IRCCS Ospedale Policlinico San MartinoGenova, ItalyContact: Matteo Bauckneht, MDTaking people
- UOC Medicina Nucleare, AOU Policlinico G.MartinoMessina, ItalyContact: Riccardo Laudicella, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Trial code
- NCT07089550
- Record updated
- 20 February 2026
- Original description
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.Read full original descriptionShow less
PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN), an Italian Multicenter Study
This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies.
The primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population.
This study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.
Inclusion: Histological diagnosis of advanced prostate cancer (excluding neuroendocrine carcinoma); Patients undergoing PSMA PET for pre-treatment disease staging; Candidates to receive one or more of the following systemic therapies, in combination or alone: abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, olaparib, radiotherapy, lutetium-177-PSMA, actinium-225-PSMA; Provision of signed informed consent for study participation and data handling.
Exclusion: Presence of another concurrent malignancy, with the exception of non-melanoma skin cancer; Prostate cancer with a known significant neuroendocrine component; Inability to remain supine and still for the PET/CT image acquisition.